Citations 2
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Goto, Kōichi , Kim, Dong-Wan, Rha, Sun Young , Park, Joon Oh, Liu, Stephen V. , Cleary, James M. , Umemoto, Kumiko , Nagasaka, Misako , Bekaii‐Saab, Tanios , O’Kane, Grainne M. , Opdam, Frans L. , Joe, Andrew K., Wasserman, Ernesto, Stalbovskaya, Viktoriya, Ford, Jim, Jain, Lokesh , Jauhari, Shekeab , Kim, Dong‐Wan , Rohrberg, Kristoffer Staal , Calvo, Emiliano , Bekaii-Saab, Tanios S , Liu, Stephen V , Kim, Dong-Wan , Schram, Alison M. , Macarulla, Teresa , Hollebecque, Antoine , O’Reilly, Eileen M. , Ou, Sai‐Hong Ignatius , Rodon, Jordi , Nishino, Kazumi , Duruisseaux, M. , Neuzillet, Cindy , Weinberg, Benjamin A. , Calvo, Emiliano , Springfeld, Christoph , Reiss, Kim A. , Adeyemi, Shola, Drilon, Alexander , O'Kane, Grainne M.
New England Journal of Medicine | February 5, 2025 | Volume: 392 | Issue: 6 | Pages: 566-576
ReTHINK: A randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients.
Reiter, Andreas , Bharathy, Savita, Iommazzo, Dana, Stalbovskaya, Viktoriya, Gopalakrishna, Prashanth, Passamonti, Francesco , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mesa, Ruben A.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7080-TPS7080